HUE031053T2 - Arilpiperazin származékok készítményei, szintézise és alkalmazási módszerei - Google Patents

Arilpiperazin származékok készítményei, szintézise és alkalmazási módszerei Download PDF

Info

Publication number
HUE031053T2
HUE031053T2 HUE10746949A HUE10746949A HUE031053T2 HU E031053 T2 HUE031053 T2 HU E031053T2 HU E10746949 A HUE10746949 A HU E10746949A HU E10746949 A HUE10746949 A HU E10746949A HU E031053 T2 HUE031053 T2 HU E031053T2
Authority
HU
Hungary
Prior art keywords
jelen
compounds
compound
substituted
alkyl
Prior art date
Application number
HUE10746949A
Other languages
English (en)
Inventor
Laxminarayan Bhat
Prabhu Prasad Mohapatra
Kouacou Adiey
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of HUE031053T2 publication Critical patent/HUE031053T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Claims (6)

  1. Anlpiptrxím származékok Sjtabaiai m i igém· pontok i · Bgv (1|>:
    képletü vegyük* vagy gyógyászatUag elfogadható bő)X aromerje. raoettwga vagy axok diaszíeroonei cU-pyv, ab** A -O-tCíbír- "Ν"ΑΊ!;Ρ-, *. H-OnHVv* λ<· H'W«M;ií-Uir> -CH-SaUby. CUBA t ti Oi -, ΛίΙ x ^ΙϊμΠ'Λ·, -C'ibAHCiUHtlbkr, -ni>-C{0)-NH-iCI by sauyACIbpAyCnAHA^-bAIiî^ ahoi n ériéke By B jdeokSe (A S, vagy NR'; xalameroni Rs és ΙΓ egynapid függetlenül hidrogénatom, halogénatom, sam alkeocaopom és •válamtimyí'E^ &amp;\'M,ilggeilemü h!dropbl:iöií,:élkl!? szubsztitöáll alléd, ank s/obo/thaali aök yríUikd, s/ubazdtuáh adlalük ukloaikih s/ubs/túnali eiUoyíkü, clUoheieroalkd, sxulxoultuáh eiklokieroalkik hetem&amp;rik s/nhsxik«ali hderoank hetetoanialkd, s/ukvtita;dt heten,unlalkit, acHatkitoxi-karbond, yelWulkitoxokarbonik aedalUyxsk'yhoHdammo, aatoxrhyioxikasbonshyobno, alkóv, aikovkadunuk ÄoxikarbeBR^iôMpâlkéï^îkMkiiïMkii^mîïOj-âÉfeuitlmk AllilszÄml% alfeiltldo, ajBihra aikilsgim. ar!lafi|pthsít diallikiaBye, arîklkoxi, ariialk<«ikar|H)h|aikDxi^ auLdk>'XíkaíK>niki.lkiLaaioo, auloxi-karhooiL aniostkarbonilnikov, aníoxikurbomlalkilamina, kaihoxi. karbamoü, karba nun, karbonát. eiano. haiogenaiom, net s X r5oï\ikarboaxk:morox' v 'donat v-día, ή o v u s am >z«j οπλιηΛ söpört ahol R\ R\ RUR\ R\ R. és Rh é? A adott cselben 'î I (üeoiórhnnn '11 (tr Uhuink :'í , 'VR 'R 5Λ\ sO,' !\ 'V, >.d\k ve \ Ak^eme t/» * -ppat sz«es;o null w nle\ a ssuhsztituáh kifejtés azt jelenti, hop$i egy vagy több hídrogéáatÍRreipd%fólÍ^g^Ípp. 'K. "R"b -Ο-, «Ο. -OR^R AR'R -S »S. -NRVíR?\ -NR54. ~ÜXa -€N, -OCR -SCN. -NO, -A's "N\ ΑκΑρ.κ ARAROII. RRÛROIV^ X>StO)dAR *P{OKO>>,·. -OF(0)K>R':RiOR'· R -C(0}R \ RRSíR5', ΧλΌ}<ΒΓ\ -CíOyí^R55, -UO)0-, -C\S)ÖRs\ ΛίΓ'ΰΟ) RmR' . \R* OíNITkK'V'^s ONtO^R^R" csoportok Uvüi sahs/utl szobenituenasdl van kicserélve^Jte|pfceí«^||:;^yi^td! Rlgptlettiliialogénaíom; é$ vuhmotmy RH R ', R'sesR’ extrástól fúggoduúil hkirognnatom. alkik an.L ankilMI V N í. dVd 0 kkrisetu oa ihd heiemaíkss.hviuo ou ' <.i.v I tteioe ikilk.ks'pon
  2. 2. Az I. igénypont óPHntl pif
    köpktü vegyük! ^ \> ' 'Op ? ípontont oviink * a' »ot no x n 11 > * * * A * 1 Η ) O OirCBr, R.'Hr So;€B>)í!% vag) *(C'i-l:}s-S-CH2-a l·- osoport.
  3. 4.. Az. 1. vagy 2. A jelentése XMCII Ar csoport.
  4. 5. Az I. vagy 2. igénypont szerinti vegyüfeu ahol A jelentőse ••MMAXÜHCíIkk'-, Ut'*\* ΛΟ (tűri 'Ibi ηΛ<^Ι1'\ sags np HA -OOkMKHI Ol· csopntt. e Art seen igénypont ^ ohets'Oeo'.heR .'Ja·»! R'»e'.ovit ίο B 7 Az l. vagy 2, Igénypont szerinti xegyilou ahol B jelennie CX 8, A%: i, igiüypÄt säIiîîî.. Hi 14%·
    MjsietÖ'Vëggülat vagy gyégyfesftihg etfegklhtó sája vsgy köméül, fi 1. tgi^y g$»t
    kéglsiü vegyfllel vagy gyégyáagatllag glfögadbaló sígarvagy liomasjg; ahol aj R‘ - 2-Okk ón )<' = H \agy b? P2 - 2-Cl és ÍR - 3-CL Kk Ak éi^Sig^yi1éntok':Mr»sélyfeé^én?\ti vegyül eb.-állói a Vëgyület an&amp;nüomer fisaik vagy díasxlcreomer tiszta. I h Az előzd Igégypontök Mtmaipkesknntl végyRÍkk âhdl a vegyfilët Mfe>Ö#flÜ|a fdmil“ iában van jelen. ti,. A: tfk'» i V H$V»k 0 v \l' ' »C ' 'S 5 . \ ** 0 alítnuási mono depamsn ÍV receptorokra; aiV, nuoe neue verokvon ' i , % a\epr<\okn», xaeo ttóftmiáM TuiUat 'sXcrC'tomn 5-41 f» x receptorokra.: 13·, \* go&amp;vpont \ bt t o \ïkt s >ar <n, îvtt’e? abo* „ x eg'» % í J''aotiatomias suon ecetben deutémimmal helyettesítettek.
  5. 14, Gyógyászati kêsritmëuy. md\ a? 1»1.V igénypontok bármelyike szerinti vegyákteub; egy gyógyászukig elfogadható hun.kv.0k segédanyagot \ags higitészen uaisimaz,
  6. 15. Az 1-13, igénypontok bár 11. χ ktt' v s ti xog\ Itt' n»x i i^u" ί e, *n* 4 αχ >v a ’'«H te dmerx pviehcv s -\svnein\ ', trouv. rnp dars „erde'k .a.^\ee 'Utu'ikU'. ,aax depresszió kezelésében tönéné alkalmazásra.
HUE10746949A 2009-02-26 2010-02-26 Arilpiperazin származékok készítményei, szintézise és alkalmazási módszerei HUE031053T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15579109P 2009-02-26 2009-02-26

Publications (1)

Publication Number Publication Date
HUE031053T2 true HUE031053T2 (hu) 2017-06-28

Family

ID=42631516

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10746949A HUE031053T2 (hu) 2009-02-26 2010-02-26 Arilpiperazin származékok készítményei, szintézise és alkalmazási módszerei

Country Status (25)

Country Link
US (9) US8188076B2 (hu)
EP (1) EP2400968B1 (hu)
JP (1) JP5337259B2 (hu)
KR (1) KR101705727B1 (hu)
CN (2) CN106045936A (hu)
AU (1) AU2010217772B2 (hu)
BR (1) BRPI1009757B1 (hu)
CA (1) CA2753599C (hu)
CO (1) CO6430428A2 (hu)
DK (1) DK2400968T3 (hu)
ES (1) ES2605232T3 (hu)
HK (1) HK1167240A1 (hu)
HU (1) HUE031053T2 (hu)
IL (1) IL214754A (hu)
MX (1) MX2011008885A (hu)
MY (1) MY161473A (hu)
NZ (1) NZ595263A (hu)
PH (1) PH12011501669B1 (hu)
PL (1) PL2400968T3 (hu)
PT (1) PT2400968T (hu)
RU (1) RU2506262C2 (hu)
SG (1) SG173842A1 (hu)
UA (1) UA102730C2 (hu)
WO (2) WO2010099503A1 (hu)
ZA (1) ZA201106805B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595263A (en) 2009-02-26 2013-06-28 Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
WO2015157451A1 (en) 2014-04-08 2015-10-15 Reviva Pharmaceuticals, Inc. Methods for treating attention deficit hyperactivity disorder
CN107206006A (zh) * 2015-01-12 2017-09-26 雷维瓦药品公司 用于治疗与帕金森病相关联的精神病的方法
WO2016115144A1 (en) 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating alzheimer's disease
CN107206007B (zh) * 2015-01-12 2021-08-10 雷维瓦药品公司 用于治疗肺高血压的方法
GB201508864D0 (en) * 2015-05-22 2015-07-01 Glaxosmithkline Ip Dev Ltd Compounds
US20180208622A1 (en) * 2015-09-11 2018-07-26 Sun Pharmaceutical Industries Limited Stable crystalline form of regadenoson
UA125520C2 (uk) 2016-08-31 2022-04-13 Джянгсу Хенгруй Медісін Ко., Лтд. Похідні оксопіколінаміду, спосіб їх отримання та їх фармацевтичне застосування
JP7343910B2 (ja) 2017-12-28 2023-09-13 レビバ ファーマシューティカルズ，インコーポレイティド 肺線維症の治療方法
CN112618580A (zh) * 2020-12-30 2021-04-09 北京科拓恒通生物技术股份有限公司 鼠李糖乳杆菌Probio-M9及其制品用于制备治疗自闭症药物的用途
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
WO2024147096A1 (en) 2023-01-07 2024-07-11 Assia Chemical Industries Ltd. Solid state forms of brilaroxazine and brilaroxazine salts

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274194A (en) * 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
FR2035749A1 (hu) * 1969-02-06 1970-12-24 Bellon Labor Sa Roger
US3726979A (en) * 1971-04-09 1973-04-10 E Hong Method of producing serotonin antagonism
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3879393A (en) * 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
JPS5970675A (ja) * 1982-10-15 1984-04-21 Otsuka Pharmaceut Co Ltd ベンゾオキサジン誘導体
JPS60169467A (ja) 1984-02-10 1985-09-02 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
US4613598A (en) * 1984-03-13 1986-09-23 Mitsubishi Chemical Industries Limited Piperazine derivatives and their acid addition salts
US4716161A (en) 1984-04-17 1987-12-29 Mitsubishi Chemical Industries Limited Phenylpiperazine derivatives and their acid addition salts
US4711883A (en) 1985-09-30 1987-12-08 Ortho Pharmaceutical Corporation Substituted 3-(4-phenyl-1-piperazinyl)alkylquinazolin-2,4-(1H,3H) diones, methods of preparation, compositions and method of use
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US4803203A (en) 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
FR2618437B1 (fr) 1987-07-23 1989-11-17 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les medicaments qui les contiennent
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
US5234924A (en) * 1990-09-26 1993-08-10 Adir Et Compagnie Benzothiazine and benzothiazole compounds useful as analgesics
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
FR2680172B1 (fr) 1991-08-05 1993-11-19 Fabre Medicament Pierre Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
JPH05331151A (ja) 1992-05-28 1993-12-14 Kyowa Hakko Kogyo Co Ltd キノキサリン−２−オン誘導体
US5994542A (en) 1995-11-14 1999-11-30 Sumitomo Chemical Company, Limited Process for producing 1-substituted tetrahydroquinazolines
FR2755690B1 (fr) * 1996-11-08 1998-12-18 Adir Nouveaux derives aminomethyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19743435A1 (de) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
BRPI0305500B1 (pt) 2003-01-09 2018-01-23 Otsuka Pharmaceutical Co., Ltd. Processo para preparar aripiprazol
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
GEP20084567B (en) 2003-05-23 2008-12-25 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
WO2005110982A2 (en) 2004-04-07 2005-11-24 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
EP1797039A1 (en) 2004-09-13 2007-06-20 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
JP2007137818A (ja) 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd ８−ヒドロキシ−２，４（１ｈ，３ｈ）−キナゾリンジオン誘導体
WO2008024481A2 (en) * 2006-08-24 2008-02-28 Concert Pharmaceuticals Inc. 3,4-dihydro-2 (1h) - quinolinone and 2 (1h)-quinolinone derivatives
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
AU2008254585B2 (en) * 2007-05-21 2013-09-26 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US8764745B2 (en) * 2008-01-25 2014-07-01 Medtronic ATS Medical, Inc. Cryoprobe clamp having transmurality assessment window
WO2009154993A1 (en) * 2008-05-27 2009-12-23 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using piperazine based antipsychotic agents
NZ595263A (en) 2009-02-26 2013-06-28 Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
JP5331151B2 (ja) 2011-03-30 2013-10-30 日本発條株式会社 車両用シート

Also Published As

Publication number Publication date
US20150005298A1 (en) 2015-01-01
PH12011501669B1 (en) 2014-02-13
CA2753599C (en) 2017-03-14
US20120220574A1 (en) 2012-08-30
CN106045936A (zh) 2016-10-26
JP2012519182A (ja) 2012-08-23
IL214754A0 (en) 2011-11-30
PL2400968T3 (pl) 2017-04-28
EP2400968A4 (en) 2012-08-01
US9255076B2 (en) 2016-02-09
JP5337259B2 (ja) 2013-11-06
DK2400968T3 (da) 2017-01-02
US8575185B2 (en) 2013-11-05
RU2506262C2 (ru) 2014-02-10
US8431570B2 (en) 2013-04-30
EP2400968A1 (en) 2012-01-04
ZA201106805B (en) 2013-02-27
US8461154B2 (en) 2013-06-11
BRPI1009757B1 (pt) 2020-01-14
KR20120013306A (ko) 2012-02-14
NZ595263A (en) 2013-06-28
EP2400968B1 (en) 2016-09-28
US20170327477A1 (en) 2017-11-16
US8859552B2 (en) 2014-10-14
MX2011008885A (es) 2011-09-29
US9975862B2 (en) 2018-05-22
US20120220579A1 (en) 2012-08-30
ES2605232T3 (es) 2017-03-13
US20100222359A1 (en) 2010-09-02
CA2753599A1 (en) 2010-09-02
CO6430428A2 (es) 2012-04-30
AU2010217772B2 (en) 2014-10-23
AU2010217772A1 (en) 2011-10-20
US9604944B2 (en) 2017-03-28
PT2400968T (pt) 2016-12-09
US20160229821A1 (en) 2016-08-11
WO2010099502A1 (en) 2010-09-02
UA102730C2 (uk) 2013-08-12
HK1167240A1 (zh) 2012-11-23
CN102413830A (zh) 2012-04-11
SG173842A1 (en) 2011-09-29
KR101705727B1 (ko) 2017-02-10
IL214754A (en) 2014-05-28
US20140155392A1 (en) 2014-06-05
US20100216783A1 (en) 2010-08-26
US8188076B2 (en) 2012-05-29
RU2011139154A (ru) 2013-04-10
WO2010099503A1 (en) 2010-09-02
MY161473A (en) 2017-04-14
BRPI1009757A2 (pt) 2016-03-15
US8980883B2 (en) 2015-03-17
US20150166493A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
US9975862B2 (en) Arylpiperazine derivatives and methods of utilizing same
AU2008254585B2 (en) Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8207163B2 (en) Compositions, synthesis, and methods of using piperazine based antipsychotic agents